Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BEXAROTENE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

BEXAROTENE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS: Safety Overview

Metric BEXAROTENE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS
Total FAERS Reports 759 176
Deaths Reported 134 0
Death Rate 17.7% N/A
Hospitalizations 177 110
Average Patient Age 66.5 yrs 66.0 yrs
% Female Patients 42.3% 91.7%
FDA Approval Date Apr 27, 2022 N/A
Manufacturer Upsher-Smith Laboratories, Inc. N/A
Route ORAL N/A
Marketing Status Prescription N/A